Skip to content
CancerIndex

Publication

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors not recorded

J Natl Compr Canc Netw2017PMID 28275037stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
28275037
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KRAS Mutation1
Cetuximab + PanitumumabSubstitutesMalignant Colorectal NeoplasmCURATED_BROADERPredictiveASupports Resistance5accepted
EID5345

NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.

PMID 28275037 · Benson et al., 2017 · Open in CIViC

civic
NRAS Mutation1
Cetuximab + PanitumumabSubstitutesMalignant Colorectal NeoplasmCURATED_BROADERPredictiveASupports Resistance4accepted
EID5344

NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.

PMID 28275037 · Benson et al., 2017 · Open in CIViC

civic